NANO-PHOTOCRYSTAL DRUG DELIVERY OF NATURAL PRODUCT

Nanotechnology-based drug delivery systems address key limitations of traditional drug administration by enhancing drug solubility, stability, bioavailability, and enabling targeted delivery. Nanoparticles improve therapeutic outcomes while reducing systemic toxicity, making them especially valuable in treating cancer and chronic diseases. A key challenge remains the effective delivery of poorly water-soluble drugs, which these systems aim to overcome through innovative formulations and carrier designs. For example, the development of albumin-bound paclitaxel nanoparticles significantly improved the safety profile and therapeutic performance of paclitaxel by enhancing solubility and reducing toxicity. Similarly, nanoparticle encapsulation of natural compounds such as ginkgo biloba extract has demonstrated improved stability, prolonged drug release, and enhanced tissue distribution. Despite these advancements, several challenges remain, including nanoparticle toxicity, physicochemical instability, large-scale manufacturing difficulties, immunogenicity, and complex regulatory requirements, which limit their widespread clinical application. The future of nanoparticle-based dds is highly promising, with potential applications in antitumor therapy, gene therapy, radiotherapy, vaccine delivery, protein delivery, and the treatment of chronic illness. Emerging technologies such as multifunctional nanoparticles, theragnostic systems, and near-infrared-ii responsive nanocarriers offer opportunities for simultaneous diagnosis, targeted therapy, and real-time monitoring of treatment outcomes. Furthermore, advances in photodynamic and photothermal therapies have expanded the role of nanoparticles in cancer treatment. Continued research focusing on biocompatibility, biodegradability, eco-friendly synthesis, and scalable manufacturing processes will be necessary for successful clinical translation and global accessibility. All things considered, drug delivery systems based on nanoparticles offer a revolutionary platform for the creation of safer, more efficient, and individualized treatment approaches.

• Andreani, T., Cheng, R., Elbadri, K., Ferro, C., & Menezes, T. (2024). Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges. Drug Delivery and Translational Research, 14: 2845–2916. https://doi.org/10.1007/s13346-024-01649-z
• Senjab, R. M., AlSawaftah, N., Abuwatfa, W. H., & Husseini, G. A. (2024). Advances in liposomal nanotechnology: from concept to clinics. RSC Pharmaceutics, 1: 928–948. https://doi.org/10.1039/D4PM00176A
• Wang, Y., Zhao, Q., & Liu, Z. (2023). Nano-delivery systems for alkaloid-based therapeutics in cancer treatment. International Journal of Pharmaceutics, 642: 123187. https://doi.org/10.1016/j.ijpharm.2023.123187
• Chen, X., Li, H., & Zhang, T. (2024). Advances in nanoparticle-mediated delivery of natural alkaloids for biomedical applications. Drug Delivery, 31(1): 234–248. https://doi.org/10.1080/10717544.2024.2301145
• Khan, H., Ullah, H., & Tundis, R. (2023). Flavonoid nanoformulations for enhanced bioavailability and anticancer activity. Pharmaceutics, 15(9): 2245. https://doi.org/10.3390/pharmaceutics15092245
• Aiello, P., Consalvi, S., Poce, G., & Raguzzini, A. (2024). Nanotechnology-based delivery systems for polyphenols in chronic disease therapy. Nanomedicine, 52: 102721. https://doi.org/10.1016/j.nano.2024.102721
• Zhang, L., Sun, Y., & Wu, J. (2024). Terpenoid-loaded nanoparticles for targeted anticancer therapy: recent advances and future perspectives. Journal of Controlled Release, 367: 620–638. https://doi.org/10.1016/j.jconrel.2024.01.018
• Müller, R. H., Gohla, S., & Keck, C. M. (2023). State of the art of nanocrystals for drug delivery applications. European Journal of Pharmaceutics and Biopharmaceutics, 189: 45–61.
• Patel, V. R., Shah, D. A., & Patel, H. K. (2024). Top-down and bottom-up technologies for pharmaceutical nanocrystals: recent developments and future prospects. Asian Journal of Pharmaceutical Sciences, 19(2): 210–228.
• Zhang, X., Li, Y., Huang, Q., & Wu, T. (2024). Supercritical fluid technology in nanocrystal preparation for poorly soluble drugs. Journal of Drug Delivery Science and Technology, 86: 104789.
• Zhang, Y., Chan, H. F., & Leong, K. W. (2023). Advanced materials and processing for drug delivery: the past and the future. Advanced Drug Delivery Reviews, 197: 114806.
• Patel, V. R., Shah, D. A., & Patel, H. K. (2024). Nanoparticle-based drug delivery systems: mechanisms and controlled release strategies. Asian Journal of Pharmaceutical Sciences, 19(3): 245–262.
• Liu, X., Sun, J., & Huang, Y. (2024). PEGylated nanoparticles for targeted drug delivery and prolonged circulation. International Journal of Pharmaceutics, 667: 124915.
• Maeda, H., & Khatami, M. (2023). Enhanced permeability and retention effect for tumor-targeted nanomedicine: current status and future prospects. Nanomedicine, 48: 102640.
• Sharma, A., Gupta, N., & Singh, R. (2024). Active targeting strategies in nanoparticle-mediated drug delivery systems. Journal of Controlled Release, 368: 445–460.
• Unnikrishnan, G., Joy, A., Megha, M., Kolanthai, E., & Senthilkumar, M. (2023). Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review. Discover Nano, 18: 157.
• Haripriyaa, M., & Suthindhiran, K. (2023). Pharmacokinetics of nanoparticles: current knowledge, future directions and its implications in drug delivery. Future Journal of Pharmaceutical Sciences, 9: 113.
• Sharma, D. K., Pattnaik, G., & Behera, A. L. (2023). Development and in-vitro, in-vivo evaluation of Pioglitazone-loaded polymeric nanoparticles using central composite design surface response methodology. OpenNano, 11: 100141.
• Bhavyasri, K., Reddy, B. A., & Sumakanth, M. (2023). Analytical methods for quality control of nanoformulations: A review. Asian Journal of Pharmaceutical and Clinical Research, 16(10): 1–6.
• Zhang, Y., Liu, X., & Chen, H. (2024). Effects of nanoparticle size, shape, and zeta potential on drug delivery. International Journal of Pharmaceutics, 666: 124799.
• Gradishar, W. J., Tjulandin, S., Davidson, N., et al. (2023). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 41(12):   2201–2210.
• Jin, Y., Zhang, B., & Li, H. (2023). Niosome-based delivery systems for enhancing bioavailability of Ginkgo biloba extract. International Journal of Pharmaceutics, 643: 123215.
• Torchilin, V. P. (2023). Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Nature Reviews Drug Discovery, 22(5): 387–405.
• Li, X., Wang, Y., & Chen, Q. (2024). Nanoparticle-based photodynamic and photothermal therapies for cancer treatment. Advanced Functional Materials, 34(8): 2401125.
• Zhang, H., Liu, J., & Sun, T. (2024). NIR-II responsive nanomaterials for biomedical applications and cancer therapy. Nano Today, 56: 102214.